Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | EZH2 | Q15910 | 6/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SERPINH1 | P50454 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13280720 | 0.99 | EZH2 (0.40) | MEN1KMT2AEZH2OPRK1TSHR | |
| SCHEMBL13280289 | 0.97 | MEN1 (0.41) | MEN1KMT2AEZH2OPRK1TSHR | |
| SCHEMBL13280137 | 0.90 | EZH2 (0.46) | EZH2 | |
| SCHEMBL13279941 | 0.87 | GAA (0.37) | MEN1KMT2AEZH2OPRK1ALDH1A1 | |
| SCHEMBL15710220 | 0.86 | OPRK1 (0.40) | MEN1KMT2AOPRK1TSHRSERPINH1 | |
| SCHEMBL18829944 | 0.85 | EZH2 (0.41) | EZH2OPRK1NPC1ALDH1A1 | |
| SCHEMBL13468049 | 0.85 | EZH2 (0.39) | MEN1KMT2AEZH2TSHRRAB9A | |
| SCHEMBL13280599 | 0.85 | GAA (0.41) | EZH2TSHRRAB9ANPC1ALDH1A1 | |
| SCHEMBL13468175 | 0.83 | EZH2 (0.53) | EZH2 | |
| SCHEMBL18829978 | 0.83 | EZH2 (0.40) | EZH2OPRK1NPC1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3470396-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3165520-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme Inc (US) | 2017-05-10 | — | — | EP | disclosed |
| US-9376422-B2 | Dihidropyridin-2-one benzamine compounds | Epizyme, Inc. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20140142083-A1 | Substituted Benzene Compounds | Epizyme, Inc. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142083-A1 | Substituted Benzene Compounds | Epizyme, Inc. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142083-A1 | Substituted Benzene Compounds | Epizyme, Inc. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142083-A1 | Substituted Benzene Compounds | CYP1B1, TP53, VHL | MEN1 2339/4885KMT2A 1120/4885EZH2 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.